Myelodysplastic syndromes

Common Name(s)

Myelodysplastic syndromes, MYELODYSPLASTIC SYNDROME

Myelodysplastic syndromes (MDS) are a rare group of blood disorders characterized by abnormal development of blood cells within the bone marrow. Individuals with MDS have abnormally low blood cell levels (low blood counts). Signs and symptoms associated with MDS include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. In some cases, MDS may progress to bone marrow failure or an acute leukemia. The exact cause of MDS is unknown. It sometimes runs in families, but no disease-causing gene has been identified. Treatment depends on the affected individual's age, general health, and type of MDS and may include red cell and/or platelet transfusions and antibiotics.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

http://www.aamds.org/

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

http://www.nbmtlink.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Myelodysplastic syndromes" returned 798 free, full-text research articles on human participants. First 3 results:

Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.
 

Author(s): Yasuyoshi Morita, Yasuhiro Maeda, Terufumi Yamaguchi, Fumiaki Urase, Shuhei Kawata, Hitoshi Hanamoto, Kazuo Tsubaki, Jun Ishikawa, Hirohiko Shibayama, Itaru Matsumura, Mitsuhiro Matsuda

Journal: Cancer Sci.. 2018 Oct;109(10):3209-3215.

 

Although azacitidine is the first-line drug for higher-risk myelodysplastic syndrome (MDS) patients, its efficacy for lower-risk MDS remains unestablished. Therefore, we conducted a prospective study to examine the efficacy and safety of a 5-day regimen of azacitidine (AZA-5) for ...

Last Updated: 31 Dec 1969

Go To URL
Impaired Mitophagy of Nucleated Erythroid Cells Leads to Anemia in Patients with Myelodysplastic Syndromes.
 

Author(s): Huijuan Jiang, Liyan Yang, Lifang Guo, Ningbo Cui, Gaochao Zhang, Chunyan Liu, Limin Xing, Zonghong Shao, Huaquan Wang

Journal:

 

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders characterized by cytopenia and dysplasia. Anemia is the most common symptom in patients with MDS. Mitophagy and mitochondrial dysfunction might be involved in the development of MDS. In this study, ...

Last Updated: 31 Dec 1969

Go To URL
Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders.
 

Author(s): Julie Schanz, Naciye Cevik, Christa Fonatsch, Friederike Braulke, Katayoon Shirneshan, Ulrike Bacher, Detlef Haase

Journal:

 

Clonal cytogenetic evolution (CE) (i.e., acquisition of new chromosomal aberrations over time) is relevant for the progression of myelodysplastic syndromes (MDS). We performed detailed analysis of CE in 729 patients with MDS and related disorders. Patients with CE showed shorter survival ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Myelodysplastic syndromes" returned 154 free, full-text review articles on human participants. First 3 results:

Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis.
 

Author(s): Chong Gao, Jia Wang, Ya Li, Huan Zhao, Ruibai Li, Li Hou, Yayue Zhang, Shaodan Tian, Huan Liang, Chong Wang, Xinyi Chen, Jing Wang

Journal: Medicine (Baltimore). 2018 Aug;97(34):e11860.

 

Hypomethylating agents (HMAs) are believed to have reliable efficacy in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Meanwhile, the adverse events of HMAs have become an increasing concern. There is, however, no systematic meta-analysis available to evaluate ...

Last Updated: 31 Dec 1969

Go To URL
Histopathology in the diagnosis of high-risk myelodysplastic syndromes.
 

Author(s): Hidekazu Kayano

Journal: J Clin Exp Hematop. ;58(2):51-60.

 

Last Updated: 31 Dec 1969

Go To URL
Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia.
 

Author(s): Douglas Tremblay, Kelsey Sokol, Sheena Bhalla, Raajit Rampal, John O Mascarenhas

Journal:

 

The advent of high-throughput gene sequencing has revolutionized our understanding of the genetic mutations that drive myeloid malignancies. While these mutations are of interest pathobiologically, they are increasingly being recognized as clinically meaningful in providing diagnostic, ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)
 

Status: Not yet recruiting

Condition Summary: Myelodysplastic Syndromes

 

Last Updated: 12 Jun 2017

Go to URL
A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome
 

Status: Not yet recruiting

Condition Summary: Myelodysplastic Syndrome (MDS)

 

Last Updated: 31 Jul 2018

Go to URL